Neuren Pharmaceuticals announced the appointment of Dianne Angus, Patrick Davies and Jenny Harry as non-executive directors. The new directors bring skills, diversity and experience in drug development and commercialisation that are highly relevant to Neuren as a leading developer of new treatments for neurological disorders. Following these appointments, the composition of the Neuren board will be 4 independent non- executive directors and 2 executive directors. Dianne Angus is currently interim CEO of the Victorian Australian Medical Association (AMA) and was formerly Chief Operating Officer of the neurological drug development company Prana Biotechnology. Dianne is also a registered Patent and Trademark Attorney. Patrick Davies has held executive management roles in the healthcare industry for over twenty years, including leading Symbion then EBOS Group as CEO for the last ten years through a period of growth in enterprise value from approximately $450 million to in excess of $3.1 billion. Dr. Jenny Harry is currently CEO of drug development company Ondek and was formerly CEO and Managing Director of Tyrian Diagnostics, leading its transformation and the commercialization of its first diagnostic product.